PL2861573T3 - Pochodne oksatiazyny jako środki przeciwbakteryjne i przeciwnowotworowe - Google Patents

Pochodne oksatiazyny jako środki przeciwbakteryjne i przeciwnowotworowe

Info

Publication number
PL2861573T3
PL2861573T3 PL13734162T PL13734162T PL2861573T3 PL 2861573 T3 PL2861573 T3 PL 2861573T3 PL 13734162 T PL13734162 T PL 13734162T PL 13734162 T PL13734162 T PL 13734162T PL 2861573 T3 PL2861573 T3 PL 2861573T3
Authority
PL
Poland
Prior art keywords
antibacterial
anticancer agents
oxathiazine
derivatives
oxathiazine derivatives
Prior art date
Application number
PL13734162T
Other languages
English (en)
Inventor
Rolf W. Pfirrmann
Original Assignee
Geistlich Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geistlich Pharma Ag filed Critical Geistlich Pharma Ag
Publication of PL2861573T3 publication Critical patent/PL2861573T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/10—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms two oxygen atoms and one sulfur atom, e.g. cyclic sulfates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL13734162T 2012-06-18 2013-06-17 Pochodne oksatiazyny jako środki przeciwbakteryjne i przeciwnowotworowe PL2861573T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261661092P 2012-06-18 2012-06-18
US201261694452P 2012-08-29 2012-08-29
PCT/IB2013/001261 WO2013190355A1 (en) 2012-06-18 2013-06-17 Oxathiazine derivatives as antibacterial and anticancer agents
EP13734162.4A EP2861573B1 (en) 2012-06-18 2013-06-17 Oxathiazine derivatives as antibacterial and anticancer agents.

Publications (1)

Publication Number Publication Date
PL2861573T3 true PL2861573T3 (pl) 2018-02-28

Family

ID=48746589

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13734162T PL2861573T3 (pl) 2012-06-18 2013-06-17 Pochodne oksatiazyny jako środki przeciwbakteryjne i przeciwnowotworowe

Country Status (8)

Country Link
US (3) US9241943B2 (pl)
EP (1) EP2861573B1 (pl)
DK (1) DK2861573T3 (pl)
ES (1) ES2644870T3 (pl)
HU (1) HUE034822T2 (pl)
PL (1) PL2861573T3 (pl)
PT (1) PT2861573T (pl)
WO (1) WO2013190355A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241943B2 (en) * 2012-06-18 2016-01-26 Geistlich Pharma Ag Oxathiazine derivatives as antibacterial and anticancer agents
SMT202200091T1 (it) * 2014-12-19 2022-03-21 Geistlich Pharma Ag Processi per preparare composti simili a ossatiazina
US11591302B2 (en) 2014-12-19 2023-02-28 Geistlich Pharm A Ag Processes for preparing oxathiazin-like compounds
US11541061B2 (en) 2016-01-11 2023-01-03 Cormedix Inc. Neuroblastoma treatment with taurolidine hydrolysis products
US20190381060A1 (en) 2016-01-11 2019-12-19 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
CA3018145C (en) * 2016-03-18 2024-09-17 Persevere Therapeutics Inc. TREATMENT METHOD FOR TRIPLE-NEGATIVE BREAST CANCER
CN109476615A (zh) 2016-04-07 2019-03-15 盖斯特里希医药公司 制备噁噻嗪类化合物的方法
WO2018086993A1 (en) * 2016-11-14 2018-05-17 Synthon Biopharmaceuticals B.V. PROCESS FOR THE PREPARATION OF MONO-PROTECTED alpha,omega-DIAMINO ALKANES
EP3843745A4 (en) * 2018-08-28 2022-06-15 CorMedix Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROBLASTOMA IN A JUVENILE MAMMALIAN BODY
CN114096255B (zh) * 2019-05-22 2024-09-10 盖斯特里希医药公司 用于治疗、预防、抑制或减少细胞因子释放的噁噻嗪二氧化物
US20220313702A1 (en) * 2019-05-22 2022-10-06 Geistlich Pharma Ag Oxathiazin compounds for inhibiting gapdh
BR112023000308A2 (pt) * 2020-07-06 2023-03-28 Acad Of Military Medical Sciences Uso de taurolidina contra vírus
WO2022229907A1 (en) * 2021-04-29 2022-11-03 Geistlich Pharma Ag Antimicrobial and anticancer agents
EP4565240A1 (en) * 2022-08-05 2025-06-11 Geistlich Pharma AG Combination therapy for treating cancers
CN118724762A (zh) * 2024-06-24 2024-10-01 湖南增达生物科技有限公司 一种牛磺酸的制备新工艺

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1160443B (de) * 1961-11-30 1964-01-02 Hoechst Ag Verfahren zur Herstellung von Tetrahydro-oxathiazin-dioxyden
DE1234988B (de) 1964-11-28 1967-02-23 Bayer Ag Verfahren zur Herstellung von Copolymerisaten des Trioxans
GB8617482D0 (en) 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition
US6117868A (en) 1998-09-16 2000-09-12 Ed. Geistlich Sohne Ag Fur Chemische Industrie Treatment of gastrointestinal ulcers or gastritis caused by microbial infection
EP1246617B1 (en) * 1999-12-06 2006-09-13 Rhode Island Hospital Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of ovarian cancer
US9241943B2 (en) * 2012-06-18 2016-01-26 Geistlich Pharma Ag Oxathiazine derivatives as antibacterial and anticancer agents

Also Published As

Publication number Publication date
DK2861573T3 (da) 2017-11-13
PT2861573T (pt) 2017-11-14
US20170196876A1 (en) 2017-07-13
EP2861573B1 (en) 2017-08-30
US20150182534A1 (en) 2015-07-02
US9624187B2 (en) 2017-04-18
EP2861573A1 (en) 2015-04-22
WO2013190355A1 (en) 2013-12-27
ES2644870T3 (es) 2017-11-30
US9844555B2 (en) 2017-12-19
US9241943B2 (en) 2016-01-26
US20160159759A1 (en) 2016-06-09
HUE034822T2 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
PT2861573T (pt) Derivados de oxatiazina como agentes antibacterianos e anticancerígeno
ZA201506880B (en) Quinolines derivatives as novel anticancer agents
IL233863A0 (en) Pyridine derivatives, preparations containing them and their uses
GB201304967D0 (en) .
GB201204183D0 (en) .
IL237068A (en) 1,3-dioxanomorphides and 1,3-dioxanocodides
EP3016716A4 (en) Anticancer combinations
EP2873701A4 (en) ORGANIC-INORGANIC COMPLEX, AND COMPOSITION FOR THE FORMATION OF SAID COMPLEX
EP2832346A4 (en) AQUEOUS DISPERSED COMPOSITION
EP2864362A4 (en) ANTICANCER TREATMENT
IL233682A0 (en) Modified phenylazole derivatives, preparations containing them and their uses
IL237538A0 (en) Amphiphilic compounds, their preparations and uses
GB201603522D0 (en) Pyrazolochalcones as potential anticancer agents
GB201214551D0 (en) Anticancer treatment
GB201218175D0 (en) Anticancer treatments
AU2013903103A0 (en) Acrolein-Polymers, their Compositions and In-vivo Uses
GB201212457D0 (en) Smart-road-smart-smart-vehicle synergy
AU2012904225A0 (en) 28.8Scanfit
AU2012901213A0 (en) 28.8trackside
GB201207426D0 (en) .
GB201206866D0 (en) .
GB201206865D0 (en) .
GB201205844D0 (en) .
GB201200117D0 (en) .
GB201207429D0 (en) www.findmyark.com